Aclaris Therapeutics, Inc. Net Cash Provided by (Used in) Investing Activities, Continuing Operations
Aclaris Therapeutics, Inc. (ACRS) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of $5.96 million for the 3-month period ending 2017-03-31, per its 10-Q filed 2017-05-09.
Discontinued › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2017-05-09
- Aclaris Therapeutics, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-03-31 was $5.96M, a 41.46% decline year-over-year.
- Aclaris Therapeutics, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2016-12-31 was -$77.82M.
- Aclaris Therapeutics, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2016-09-30 was -$4.13M.
- Aclaris Therapeutics, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2016-06-30 was $9.87M, a 100.98% increase year-over-year.
- Aclaris Therapeutics, Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2016 was -$61.90M.
- Aclaris Therapeutics, Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2015 was -$76.95M.
- Aclaris Therapeutics, Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2014 was -$1.78M.
- Aclaris Therapeutics, Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2013 was -$4.54M.
| Period end | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month |
|---|---|---|---|---|
| 2017-03-31 | $5.96M 10-Q · filed 2017-05-09 | -$71.86M derived: sum of 2 quarters · filed 2017-05-09 | -$75.99M derived: sum of 3 quarters · filed 2017-05-09 | -$66.12M derived: sum of 4 quarters · filed 2017-05-09 |
| 2016-12-31 | -$77.82M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-15 | -$81.94M derived: sum of 2 quarters · filed 2017-03-15 | -$72.08M derived: sum of 3 quarters · filed 2017-03-15 | -$61.90M 10-K · filed 2017-03-15 |
| 2016-09-30 | -$4.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | $5.74M derived: sum of 2 quarters · filed 2016-11-03 | $15.91M 10-Q · filed 2016-11-03 | -$53.57M derived: sum of 4 quarters · filed 2017-05-09 |
| 2016-06-30 | $9.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-11 | $20.04M 10-Q · filed 2016-08-11 | -$49.45M derived: sum of 3 quarters · filed 2017-05-09 | -$62.56M derived: sum of 4 quarters · filed 2017-05-09 |
| 2016-03-31 | $10.17M 10-Q · filed 2017-05-09 | -$59.31M derived: sum of 2 quarters · filed 2017-05-09 | -$72.43M derived: sum of 3 quarters · filed 2017-05-09 | -$67.52M derived: sum of 4 quarters · filed 2017-05-09 |
| 2015-12-31 | -$69.49M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-15 | -$82.61M derived: sum of 2 quarters · filed 2017-03-15 | -$77.70M derived: sum of 3 quarters · filed 2017-03-15 | -$76.95M 10-K · filed 2017-03-15 |
| 2015-09-30 | -$13.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | -$8.21M derived: sum of 2 quarters · filed 2016-11-03 | -$7.46M 10-Q · filed 2016-11-03 | -$12.83M derived: sum of 4 quarters · filed 2017-03-15 |
| 2015-06-30 | $4.91M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-11 | $5.66M 10-Q · filed 2016-08-11 | $290.00K derived: sum of 3 quarters · filed 2017-03-15 | |
| 2015-03-31 | $745.00K 10-Q · filed 2016-05-11 | -$4.62M derived: sum of 2 quarters · filed 2017-03-15 | ||
| 2014-12-31 | -$5.37M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-15 | -$1.78M 10-K · filed 2017-03-15 | ||
| 2014-09-30 | $3.59M 10-Q · filed 2015-12-03 | |||
| 2013-12-31 | -$4.54M 10-K · filed 2016-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |